OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma
Background Resistance to immune approaches poses a major challenge to effective
immunotherapy and long-term clinical outcome in multiple myeloma (MM). Here we …
immunotherapy and long-term clinical outcome in multiple myeloma (MM). Here we …
Higher TRAF6 and Fbxo 3 Expression Is With Progressive Multiple Myeloma and Blockage Of TRAF6 Inhibits Tumor Growth and Bone Resorption
M Li, S Vardanyan, J Gottlieb, C Wang, K Delijani… - 2013 - ashpublications.org
Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in
regulating the NF-kB and JNK signal transduction pathways; and, thus, is likely to promote …
regulating the NF-kB and JNK signal transduction pathways; and, thus, is likely to promote …
Transgenic Mouse Model for Translational Immunotherapy Studies on Multiple Myeloma
M Yu, V Zhou, MD Pisano, D Parashar, X Cui, S Janz - Blood, 2023 - Elsevier
Background Genetically engineered mouse models that recapitulate key immunological
features of human multiple myeloma may lend themselves to preclinical design and testing …
features of human multiple myeloma may lend themselves to preclinical design and testing …
Hypoxia-adapted multiple myeloma stem cells resist γδ-T-cell-mediated killing by modulating the mevalonate pathway
Y Sano, N Kuwabara, S Nakagawa, Y Toda… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: The prognosis of patients with multiple myeloma (MM) has recently
improved due to the emergence of new molecular targeting agents. However, MM remains …
improved due to the emergence of new molecular targeting agents. However, MM remains …
Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma
K Wang, Y Jiang, W Zheng, Z Liu, H Li, J Lou, M Gu… - PLoS …, 2013 - journals.plos.org
Rituximab is the first line drug to treat non Hodgkin's lymphoma (B-NHL) alone or in
combination with chemotherapy. However, 30–40% of B-NHL patients are unresponsive to …
combination with chemotherapy. However, 30–40% of B-NHL patients are unresponsive to …
Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype
H Fairfield, A Dudakovic, CM Khatib, M Farrell, S Costa… - Cancer research, 2021 - AACR
Bone marrow adipocytes (BMAd) have recently been implicated in accelerating bone
metastatic cancers, such as acute myelogenous leukemia and breast cancer. Importantly …
metastatic cancers, such as acute myelogenous leukemia and breast cancer. Importantly …
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
We investigate here how APRIL impacts immune regulatory T cells and directly contributes
to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment …
to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment …
[HTML][HTML] Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma
H Liu, C Xiong, J Liu, T Sun, Z Ren, Y Li, J Geng… - Biomedicine & …, 2020 - Elsevier
B lymphocyte-induced maturation protein-1 (Blimp1) is a key regulator that promotes the
terminal differentiation of mature B lymphocytes into plasma cells, and is essential for the …
terminal differentiation of mature B lymphocytes into plasma cells, and is essential for the …
[HTML][HTML] Bone Marrow Adipocyte Promotes Epithelial-Mesenchymal-Transition-like Activation in Multiple Myeloma Via CXCL-12/CXCR4 Axis
LL Shu, S Chen, J Li, W Wang, Y Liu, Y Li, HY Huang… - Blood, 2021 - Elsevier
Extra-medullary disease (EMD) in multiple myeloma (MM) is associated with poor prognosis
and resistance to chemotherapy. The bone marrow microenvironment is a key regulator of …
and resistance to chemotherapy. The bone marrow microenvironment is a key regulator of …